Swiss Healthtech Stock News

Earlier this week, Sensirion Holding reported revenue growth of 18.58% alongside a zero-debt balance sheet and solid liquidity, reinforcing its financial strength. This combination of accelerating top-line performance and a clean capital structure adds an extra layer of resilience to Sensirion’s existing growth story. Next, we’ll examine how this strong revenue momentum and debt-free position may reshape Sensirion Holding’s existing investment narrative. Capitalize on the AI...

ABB (SWX:ABBN) has announced around US$200 million of investment in its European medium voltage operations, including a new facility in Italy and upgrades across several factories, to support demand for advanced grid technologies. See our latest analysis for ABB. ABB’s recent US$200 million grid investment program comes as the stock trades at CHF82.02, with a 30-day share price return of 14.17% and a 1-year total shareholder return of 78.50%, signalling strong momentum across both shorter and...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Readers hoping to buy Burkhalter Holding AG ( VTX:BRKN ) for its dividend will need to make their move shortly, as the...

Swiss Re AG ( VTX:SREN ) last week reported its latest first-quarter results, which makes it a good time for investors...

Recent share performance and business snapshot Clariant (SWX:CLN) has come into focus after a recent pullback, with the stock down about 7% over the past month and roughly 7% over the past 3 months, prompting investors to reassess its fundamentals. The Switzerland based specialty chemicals company operates across three main segments: Care Chemicals, Catalysts, and Adsorbents & Additives, serving customers across Europe, the Americas, Asia and the Middle East & Africa. See our latest analysis...

The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. added pressure to markets. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities that are potentially trading below their intrinsic value amidst fluctuating market...

In early May 2026, ams-OSRAM reported first-quarter sales of €796 million alongside a larger net loss and issued guidance for slightly softer full-year 2026 revenue due to business divestments and foreign-exchange effects. At the same time, the company highlighted progress in its Digital Photonics pivot, including a development partnership targeting AI data centers and micro LED commercialization, which has drawn renewed attention to its semiconductor portfolio. We’ll now examine how this...

Valiant Holding AG reported first-quarter 2026 results with net interest income of CHF 100.64 million and net income of CHF 33.24 million, both slightly higher than a year earlier. Despite this modest improvement, investors focused on the bank’s elevated debt levels and challenging revenue trends, which raised concerns about its financial flexibility and resilience. We’ll now examine how these weaker-than-expected earnings, alongside concerns over the high debt-to-equity ratio, shape Valiant...

Why Kuros Biosciences (SWX:KURN) is on investors’ radar today Kuros Biosciences (SWX:KURN) has drawn attention after recent share price pressure, with the stock showing a 15.1% decline over the past month and a 20.2% decline over the past 3 months. See our latest analysis for Kuros Biosciences. At the latest share price of CHF20.12, Kuros Biosciences shows weaker short term momentum, with a 1 month share price return of 15.1% decline and a year to date share price return of 24.6% decline,...

Novartis has started construction on a new radioligand therapy manufacturing facility in Denton, Texas. The Denton site expands the company’s US network for advanced cancer treatments and is part of a broader multi year, multi billion dollar US investment plan. The project is expected to support access to personalized cancer therapies and create jobs in bioengineering and advanced manufacturing. For investors following Novartis (SWX:NOVN), the Denton build out comes as the stock trades...

If you are asking whether UBS Group is priced attractively right now, the starting point is to look closely at what the current share price might already be assuming. The stock last closed at CHF 35.03, with returns of 1.5% over 7 days, 8.1% over 30 days, a 8.2% decline year to date, and gains of 38.4% over 1 year, 120.8% over 3 years and 189.1% over 5 years. Recent headlines have focused on UBS Group's role as a major global banking and wealth management group, including its ongoing...

If you are wondering whether Temenos is priced fairly or if the current share price leaves room for upside, it helps to start by looking closely at what the market has been paying for this stock recently. Temenos shares recently closed at CHF 74.20, with returns of 0.4% over 7 days, 2.3% over 30 days, a 9.0% decline year to date, and 22.6% over the past year. Together, these figures present a mixed picture of changing expectations and risk perception. Recent coverage of Temenos has focused...

If you are wondering whether Alcon at around $49.17 is starting to look like value after a tough spell, this breakdown will help you frame the opportunity and the risks. The stock has faced sharp share price pressure, with returns of a 15.5% decline over 7 days, a 19.7% decline over 30 days, a 22.6% decline year to date and a 37.9% decline over 1 year, as well as a 29.9% decline over 3 years and a 19.2% decline over 5 years. Recent coverage has focused on how this sustained weakness has put...

The investors in ams-OSRAM AG 's ( VTX:AMS ) will be rubbing their hands together with glee today, after the share...

UBS Group is signaling interest in expanding in the US through acquisitions following its integration of Credit Suisse. Leadership is highlighting growth ambitions in the Americas and pointing to recent inflows of new client assets in the region. The group has received a national US banking license and announced executive hires in key US regions to support potential expansion. UBS Group (SWX:UBSG) is trading around CHF34.94, with the stock up 39.1% over the past year and 190.3% over five...

Investors in Logitech International S.A. ( VTX:LOGN ) had a good week, as its shares rose 6.6% to close at CHF81.82...

As you might know, Geberit AG ( VTX:GEBN ) recently reported its quarterly numbers. Geberit reported in line with...

Earnings miss, weaker profit, and new buyback sharpen focus on Alcon stock Alcon (SWX:ALC) reported first quarter 2026 revenue growth supported by recent product launches and market share gains. Profit came under pressure, guidance was reaffirmed, and a US$1.5b share repurchase plan was introduced. See our latest analysis for Alcon. Alcon's latest earnings and the new US$1.5b buyback have coincided with a sharp reset in sentiment, with a 7 day share price return of a 13.6% decline and a 1...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Sunrise Communications AG ( VTX:SUNN ) stock is about to trade ex-dividend in three days. The ex-dividend date is...

Why Logitech International (SWX:LOGN) is on investors’ radar today Logitech International (SWX:LOGN) has drawn interest after recent price moves, including a 1 day return of about a 0.4% decline and gains of roughly 3.6% over the past week and 8.9% over the past month. See our latest analysis for Logitech International. Looking beyond the latest move, Logitech’s 15.1% 90 day share price return and 27.8% 1 year total shareholder return point to momentum that contrasts with a relatively flat...

Alcon (SWX:ALC) opened 2026 with Q1 revenue of US$2.7b and basic EPS of US$0.39, setting a clear marker for how the year is starting after a period where trailing 12 month revenue sat at US$10.6b and EPS at US$1.67. Over recent quarters, the company has seen revenue move from US$2.5b in Q4 2024 to around US$2.7b in Q1 2026, while quarterly EPS has ranged from US$0.36 to US$0.71. This gives investors a wide set of earnings outcomes to weigh against a reported trailing net margin of 7.7% and...

Investors may be wondering if Novartis at CHF113.54 is still offering value, or if most of the easy gains are already on the table. The stock is up 25.9% over the last year and 41.9% over 3 years, even though it shows a 1% decline over 7 days, a 7.8% decline over 30 days, and a 4.6% return year to date. Recent headlines have focused on Novartis as a large global pharmaceutical business, with investors watching how its product portfolio and pipeline shape long term expectations. This context...